Biogen (BIIB)
(Delayed Data from NSDQ)
$225.65 USD
+1.04 (0.46%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $225.71 +0.06 (0.03%) 6:34 PM ET
4-Sell of 5 4
C Value B Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BIIB 225.65 +1.04(0.46%)
Will BIIB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
Denali (DNLI) Outperforms Industry in 3 Months: Here's Why
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day
Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?
Other News for BIIB
Biogen Completes Acquisition of Human Immunology Biosciences
Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors Limiting Growth
Biogen, Eisai launch Alzheimer's drug Leqembi in China
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Black Diamond Therapeutics (BDTX) and Biogen (BIIB)
IN BRIEF: Biogen's Leqembi launches in China to treat Alzheimer's